Fig 2.tif (193.61 kB)
Effect ITPase activity on regimen associated adverse events.
figure
posted on 2018-01-12, 18:34 authored by N. Chantal Peltenburg, Jörgen Bierau, Jaap A. Bakker, Jolanda A. Schippers, Selwyn H. Lowe, Aimée D. C. Paulussen, Bianca J. C. van den Bosch, Mathie P. G. Leers, Bettina E. Hansen, Annelies VerbonThe effect of decreased ITPase activity on the occurrence of regimen associated adverse events (renal adverse events for tenofovir and gastro-intestinal and skin related adverse events for abacavir) is plotted. Odds ratio with 95% confidential interval and matching p-values are displayed. The analyses were conducted with repeated statement, adjusted for cumulative total duration of cART, cumulative duration of purine analogue therapy of all prior regimens and duration of the current regimen.
